Pfizer announced results from its Phase 2 study of inotuzumab ozogamicin for the treatment of B-cell Non-Hodgkin Lymphoma (NHL). The study evaluated 59 patients with indolent B-cell NHL refractory to rituximab, rituximab plus chemotherapy, or radioimmunotherapy. Data showed an objective response rate (ORR) of 55%, with an ORR of 62% in patients with follicular lymphoma (FL). Ten FL patients achieved a complete response, and at 12 months the rate of progression-free survival (PFS) was 50%. Results from this ongoing study showed that inotuzumab ozogamicin demonstrated clinical activity and had a similar safety profile to that previously reported.
Inotuzumab ozogamicin is an investigational, antibody-drug conjugate (ADC) comprised of a monoclonal antibody (mAb), targeting CD22, an antigen expressed in approximately 90% of B-cell malignancies.
For more information call (212) 733-2323 or visit www.pfizer.com.